<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293241</url>
  </required_header>
  <id_info>
    <org_study_id>Version 2-Aug 21, 2007</org_study_id>
    <nct_id>NCT00293241</nct_id>
  </id_info>
  <brief_title>PreFER Managed Ventricular Pacing (MVP) For Elective Replacement</brief_title>
  <official_title>PreFER MVP for Elective Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the benefit of MVP in pacemaker and implantable
      cardioverter defibrillator (ICD) patients with a history of right ventricular pacing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A number of clinical studies (Danish I, Danish II, David, MOST) over the past few years have
      shown that, in patients with intact atrioventricular (AV) conduction, unnecessary chronic
      right ventricular (RV) pacing can cause a variety of detrimental effects, including atrial
      fibrillation (AF), left ventricular (LV) dysfunction, and congestive heart failure (CHF).
      These effects are believed to result from the mechanical dyssynchrony and ventricular chamber
      dysfunction that occurs with chronic, single-site, apical ventricular stimulation.

      Therefore a new pacing modality, Managed Ventricular Pacing (MVP), was designed to give
      preference to natural heart activity by minimizing unnecessary right ventricular pacing. This
      is accomplished by automatically switching between single chamber atrial and dual-chamber
      pacing based on specific patient needs.

      MVP is an atrial-based dual-chamber pacing mode that provides functional AAI/R pacing with
      ventricular monitoring and back-up DDD/R pacing only as needed during episodes of AV block.

      The reversibility of the detrimental effects caused by ventricular pacing has been initially
      investigated in small patient populations with short pacing durations in AAI and needs
      further investigation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Event Analysis: Number of Patients Who Experienced the First Cardiovascular Hospitalization Within 2 Years Post-implant</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Time to first event of cardiovascular (CV) hospitalization from implant to 2 years post-implant.
Hospitalization is defined as:
admission to hospital involving one overnight stay or
emergency room / office visits that result in cardioversions or acute treatment of worsened cardiac condition
Cardiovascular is defined as new or worsening:
heart failure (HF),
angina,
myocardial infarction (MI),
any arrhythmia,
stroke,
transient ischemic attack (TIA),
acute peripheral vascular emergencies,
pulmonary embolism.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Event Analysis: Number of Patients Who Experienced Death or First Cardiovascular (CV) Hospitalization Within 2 Years Post-implant.</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Time to first event of death or cardiovascular (CV) hospitalization from implant to 2 years post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Event Analysis: Number of Patients With Persistent AT/AF Within 2 Years Post-implant</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Time to first event of atrial tachycardia/ atrial fibrillation (AT/AF) fulfilling one of the following criteria:
7 days in a row with device diagnostic showing 20 or more hours in AT/AF or
a cardioversion was done to terminate AT/AF or
the patient is during 2 consecutive follow-up (FU) visits in AT/AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Event Analysis: Number of Patients With Permanent AF Within 2 Years Post-implant</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Time to development of permanent AF fulfilling one of the following criteria:
7 days in a row with device diagnostic showing 20 or more hours in AT/AF and cardioversion failed or
7 days in a row with device diagnostic showing 20 or more hours in AT/AF and the investigator decides not to cardiovert the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Pacing Percentage</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Endpoint: Cumulative percentage ventricular pacing documented in the device memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction (LVEF,%) Over 2 Years Time</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Endpoint: LVEF (%) difference between 2 year post implant and baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association (NYHA) Functional Class</measure>
    <time_frame>Baseline, one year and 2 year post-implant</time_frame>
    <description>Endpoint: NYHA classification at Baseline, one year and 2 year post-implant. (Class I is considered a better category and Class IV is considered worse) I Patients with cardiac disease but resulting in no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea or anginal pain.
II Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.
III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea or anginal pain.
IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort increases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Use of Anticoagulation</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Endpoint: Use of Anticoagulation at enrollment and every follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Use of Cardiovascular Medication Over Time</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Endpoint: Use of Diuretics, ACE Inhibitors, Beta-Blockers, digitalis, calcium antagonists and antiarrhythmic drugs at enrollment, and 1month, 12 months, and 24 mnths after implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of High Voltage Therapies</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Endpoint: A high voltage therapy delivered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Event Analysis: Number of Patients Who Died Within 2 Years Post-implant</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Time to patient death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Endpoint: Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiovascular Related Hospitalizations</measure>
    <time_frame>Implant to 4 years post-implant</time_frame>
    <description>Endpoint: Number of Cardiovascular hospitalizations per subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Cardiovascular Related Hospitalizations</measure>
    <time_frame>Implant to 4 years post-implant</time_frame>
    <description>Endpoint: Duration of Cardiovascular Hospitalizations per subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Class I Pacemaker (Implantable Pulse Generator = IPG) Indication in Implantable Cardioverter Defibrillator (ICD) Patients</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Endpoint: Patient implanted with a replacement ICD developing a class 1 pacemaker indication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PR Interval, Change in QRS Duration and Change in P-wave Duration</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Endpoint: Change in PR interval, Change in QRS duration and Change in P-wave duration evaluated at enrollment and 24 Month FU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Symptoms</measure>
    <time_frame>Implant to 2 years post-implant</time_frame>
    <description>Endpoint: Symptoms evaluated at enrollment, 12 months and 24 months followup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Pacing Percentage</measure>
    <time_frame>2 years post-implant</time_frame>
    <description>Endpoint: Cumulative percentage atrial pacing documented in the device memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health State</measure>
    <time_frame>2 years post-implant</time_frame>
    <description>Endpoint: Health State evaluation with the EQ-5D questionnaire (range 0-100) . A measure of 100 is better and a measure of 0 is worse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">630</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>MVP ON</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Managed Ventricular Pacing programmed on</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVP OFF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Managed Ventricular Pacing programmed ON/OFF</intervention_name>
    <description>Device programming</description>
    <arm_group_label>MVP ON</arm_group_label>
    <arm_group_label>MVP OFF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients implanted with a dual chamber device (including atrial synchronous
             ventricular inhibited [VDD]) for a minimum time duration of 2 years

          -  Planned to be replaced or replaced with a device including the MVP feature

          -  Have had more than 40% ventricular pacing documented with their old device over a
             period of at least 4 weeks before enrollment or device replacement.

          -  Pacing should not be caused by a switch to the single chamber pacing (VVI) mode
             because of battery depletion

          -  Have signed the informed consent

          -  Have no need to change the pacing mode or the atrioventricular (AV) intervals.

        Exclusion Criteria:

          -  Patients with a cardiac resynchronization therapy (CRT) indication

          -  Permanent AF

          -  Permanent AV block

          -  Inability to complete follow-up visits at a study center.

          -  Unwillingness or inability to cooperate or give written informed consent, or the
             patient is a minor, and legal guardian refuses to give informed consent

          -  Planned cardiovascular intervention

          -  Inclusion in another clinical trial that will affect the objectives of this study

          -  Neurocardiogenic syncope as primary implantable pulse generator (IPG) indication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Piot, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Cardiologique du Nord, Saint-Denis, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aurelio Quesada, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>De Roy, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires de Mont-Godinne, Yvoir, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renato Ricci, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Filippo Neri Hospital, Rome, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianluca Botto, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Como S. Anna Hospital, Como, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milan Kozak, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fakultní nemocnice Brno Bohunice, Brno, Czech Republic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medtronic Bakken Research Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <results_first_submitted>October 9, 2014</results_first_submitted>
  <results_first_submitted_qc>June 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2015</results_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pacemaker or ICD replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study start February 2006; last patient enrolled in August 2009.</recruitment_details>
      <pre_assignment_details>Patients were electronically randomized. 25 patients were excluded from analysis due to double entry (7) or no evidence of Patient Informed Consent Form (PIC) signed (18).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MVP ON</title>
          <description>Managed Ventricular Pacing programmed on</description>
        </group>
        <group group_id="P2">
          <title>MVP OFF</title>
          <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MVP ON</title>
          <description>Managed Ventricular Pacing programmed on</description>
        </group>
        <group group_id="B2">
          <title>MVP OFF</title>
          <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="299"/>
            <count group_id="B2" value="306"/>
            <count group_id="B3" value="605"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.1" spread="10.9"/>
                    <measurement group_id="B2" value="74.3" spread="10.8"/>
                    <measurement group_id="B3" value="74.7" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Event Analysis: Number of Patients Who Experienced the First Cardiovascular Hospitalization Within 2 Years Post-implant</title>
        <description>Time to first event of cardiovascular (CV) hospitalization from implant to 2 years post-implant.
Hospitalization is defined as:
admission to hospital involving one overnight stay or
emergency room / office visits that result in cardioversions or acute treatment of worsened cardiac condition
Cardiovascular is defined as new or worsening:
heart failure (HF),
angina,
myocardial infarction (MI),
any arrhythmia,
stroke,
transient ischemic attack (TIA),
acute peripheral vascular emergencies,
pulmonary embolism.</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <population>Patients indicated for Implantable Pulse Generator (IPG) or Implantable Cardioverter Defibrillator (ICD) replacement with a history of right ventricular pacing &gt; 40%, to be allocated to either Managed Ventricular Pacing (MVP) programming, or conventional dual chamber programming (DDD) without MVP</population>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Event Analysis: Number of Patients Who Experienced the First Cardiovascular Hospitalization Within 2 Years Post-implant</title>
          <description>Time to first event of cardiovascular (CV) hospitalization from implant to 2 years post-implant.
Hospitalization is defined as:
admission to hospital involving one overnight stay or
emergency room / office visits that result in cardioversions or acute treatment of worsened cardiac condition
Cardiovascular is defined as new or worsening:
heart failure (HF),
angina,
myocardial infarction (MI),
any arrhythmia,
stroke,
transient ischemic attack (TIA),
acute peripheral vascular emergencies,
pulmonary embolism.</description>
          <population>Patients indicated for Implantable Pulse Generator (IPG) or Implantable Cardioverter Defibrillator (ICD) replacement with a history of right ventricular pacing &gt; 40%, to be allocated to either Managed Ventricular Pacing (MVP) programming, or conventional dual chamber programming (DDD) without MVP</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Time to first cardiovascular hospitalization (CV hosp)
H0:freedom from CV hosp MVP=freedom from CV hosp DDD (dual chamber conventional pacing)
Ha:freedom from CV hosp MVP≠freedom from CV hosp DDD
Power calculation:
The study is designed to detect a difference event-free survival after 2 years of 5.5 % absolute, going from 91.5% to 97%.
Test=two-sided alpha=0.05 power=80% 1:1 randomization n=600</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.927</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.612</ci_lower_limit>
            <ci_upper_limit>1.405</ci_upper_limit>
            <estimate_desc>Hospitalization:hospital admission with overnight stay;ER/office visits with cardioversions;acute treatment of worsened cardiac condition
CV:new/worsening HF,angina,MI,arrhythmia,stroke, TIA,acute peripheral vascular emergencies,pulmonary embolism</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Event Analysis: Number of Patients Who Experienced Death or First Cardiovascular (CV) Hospitalization Within 2 Years Post-implant.</title>
        <description>Time to first event of death or cardiovascular (CV) hospitalization from implant to 2 years post-implant</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Event Analysis: Number of Patients Who Experienced Death or First Cardiovascular (CV) Hospitalization Within 2 Years Post-implant.</title>
          <description>Time to first event of death or cardiovascular (CV) hospitalization from implant to 2 years post-implant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death or CV hospitalization at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death or CV hospitalization at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Time to first all cause death or cardiovascular hospitalization
H0:freedom from death or CV hospitalization=freedom from death or CV hospitalization
Ha:freedom from death or CV hospitalization≠freedom from death or CV hospitalization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.127</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.808</ci_lower_limit>
            <ci_upper_limit>1.570</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Event Analysis: Number of Patients With Persistent AT/AF Within 2 Years Post-implant</title>
        <description>Time to first event of atrial tachycardia/ atrial fibrillation (AT/AF) fulfilling one of the following criteria:
7 days in a row with device diagnostic showing 20 or more hours in AT/AF or
a cardioversion was done to terminate AT/AF or
the patient is during 2 consecutive follow-up (FU) visits in AT/AF</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Event Analysis: Number of Patients With Persistent AT/AF Within 2 Years Post-implant</title>
          <description>Time to first event of atrial tachycardia/ atrial fibrillation (AT/AF) fulfilling one of the following criteria:
7 days in a row with device diagnostic showing 20 or more hours in AT/AF or
a cardioversion was done to terminate AT/AF or
the patient is during 2 consecutive follow-up (FU) visits in AT/AF</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Persistent AT/AF at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent AT/AF at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Time to first persistent AT/AF H0:freedom from persistent AT/AF=freedom from persistent AT/AF Ha:freedom from persistent AT/AF≠freedom from persistent AT/AF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.521</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.954</ci_lower_limit>
            <ci_upper_limit>2.424</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Event Analysis: Number of Patients With Permanent AF Within 2 Years Post-implant</title>
        <description>Time to development of permanent AF fulfilling one of the following criteria:
7 days in a row with device diagnostic showing 20 or more hours in AT/AF and cardioversion failed or
7 days in a row with device diagnostic showing 20 or more hours in AT/AF and the investigator decides not to cardiovert the patient</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Event Analysis: Number of Patients With Permanent AF Within 2 Years Post-implant</title>
          <description>Time to development of permanent AF fulfilling one of the following criteria:
7 days in a row with device diagnostic showing 20 or more hours in AT/AF and cardioversion failed or
7 days in a row with device diagnostic showing 20 or more hours in AT/AF and the investigator decides not to cardiovert the patient</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Permanent AF at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Permanent AF at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Time to permanent AF H0:freedom from permanent AF=freedom from permanent AF Ha:freedom from permanent AF≠freedom from permanent AF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.425</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.573</ci_lower_limit>
            <ci_upper_limit>3.543</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Pacing Percentage</title>
        <description>Endpoint: Cumulative percentage ventricular pacing documented in the device memory</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Pacing Percentage</title>
          <description>Endpoint: Cumulative percentage ventricular pacing documented in the device memory</description>
          <units>Percentage Ventricular Pacing</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="41"/>
                    <measurement group_id="O2" value="86" lower_limit="40" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Wilcoxon Test for Comparison of Percentage of Ventricular Pacing (%VP) During Followup by Randomization Arm
H0:distribution %VP MVP=distribution %VP DDD
Ha:distribution %VP MVP≠distribution %VP DDD
Ha:</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Ejection Fraction (LVEF,%) Over 2 Years Time</title>
        <description>Endpoint: LVEF (%) difference between 2 year post implant and baseline</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction (LVEF,%) Over 2 Years Time</title>
          <description>Endpoint: LVEF (%) difference between 2 year post implant and baseline</description>
          <units>LVEF (%) difference</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="10.5"/>
                    <measurement group_id="O2" value="1.4" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in New York Heart Association (NYHA) Functional Class</title>
        <description>Endpoint: NYHA classification at Baseline, one year and 2 year post-implant. (Class I is considered a better category and Class IV is considered worse) I Patients with cardiac disease but resulting in no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea or anginal pain.
II Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.
III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea or anginal pain.
IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort increases.</description>
        <time_frame>Baseline, one year and 2 year post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Change in New York Heart Association (NYHA) Functional Class</title>
          <description>Endpoint: NYHA classification at Baseline, one year and 2 year post-implant. (Class I is considered a better category and Class IV is considered worse) I Patients with cardiac disease but resulting in no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea or anginal pain.
II Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.
III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea or anginal pain.
IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort increases.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Heart Failure (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class I (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class II (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class IV (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Heart Failure (12-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class I (12-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class II (12-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III (12-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class IV (12-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Heart Failure (24-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class I (24-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class II (24-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III (24-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class IV (24-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Use of Anticoagulation</title>
        <description>Endpoint: Use of Anticoagulation at enrollment and every follow-up visit</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Use of Anticoagulation</title>
          <description>Endpoint: Use of Anticoagulation at enrollment and every follow-up visit</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with Medication Records (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298"/>
                    <measurement group_id="O2" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Using Anticoagulants (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Medication Records (1-month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                    <measurement group_id="O2" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Changing Anticoagulants Use (1-month)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Medication Records (12-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Changing Anticoagulants Use (12-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Medication Records (24-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients Changing Anticoagulants Use (24-months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Repeated measures logistic regression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Repeated measures logistic regression</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Use of Cardiovascular Medication Over Time</title>
        <description>Endpoint: Use of Diuretics, ACE Inhibitors, Beta-Blockers, digitalis, calcium antagonists and antiarrhythmic drugs at enrollment, and 1month, 12 months, and 24 mnths after implant</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Use of Cardiovascular Medication Over Time</title>
          <description>Endpoint: Use of Diuretics, ACE Inhibitors, Beta-Blockers, digitalis, calcium antagonists and antiarrhythmic drugs at enrollment, and 1month, 12 months, and 24 mnths after implant</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Beta-blockers (Baseline), n=298, 304</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digitalis/digoxin (Baseline), n=298, 304</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium antagonists (Baseline), n=298, 304</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antiarrhythmic drugs (Baseline), n=298, 304</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta-blockers (1-month), n=271, 285</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digitalis/digoxin (1-month), n=271, 285</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium antagonists (1-month), n=271, 285</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antiarrhythmic drugs (1-month), n=271, 285</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta-blockers (12-months), n=246, 257</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digitalis/digoxin (12-months), n=246, 257</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium antagonists (12-months), n=246, 257</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antiarrhythmic drugs (12-months), n=246, 257</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta-blockers (24-months), n=226, 231</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digitalis/digoxin (24-months), n=226, 231</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium antagonists (24-months), n=226, 231</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antiarrhythmic drugs (24-month), n=226, 231</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Repeated measures logistic regression H0:Change in Beta-blockers=Change in Beta-blockers Ha:Change in Beta-blockers≠Change in Beta-blockers</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Repeated measures logistic regression H0:Change in Digitalis/digoxin=Change in Digitalis/digoxin Ha:Change in Digitalis/digoxin≠Change in Digitalis/digoxin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Repeated measures logistic regression H0:Change in Calcium antagonists=Change in Calcium antagonists Ha:Change in Calcium antagonists≠Change in Calcium antagonists</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.55</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Repeated measures logistic regression H0:Change in Antiarrhythmic drug=Change in Antiarrhythmic drug Ha:Change in Antiarrhythmic drug≠Change in Antiarrhythmic drug</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of High Voltage Therapies</title>
        <description>Endpoint: A high voltage therapy delivered</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of High Voltage Therapies</title>
          <description>Endpoint: A high voltage therapy delivered</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Event Analysis: Number of Patients Who Died Within 2 Years Post-implant</title>
        <description>Time to patient death from any cause</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP Off</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Event Analysis: Number of Patients Who Died Within 2 Years Post-implant</title>
          <description>Time to patient death from any cause</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All-Cause Death at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-Cause Death at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis:Time to all-cause death
H0:survival MVP ON=survival MVP OFF Ha:survival MVP ON≠survival MVP OFF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.243</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.803</ci_lower_limit>
            <ci_upper_limit>1.923</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke</title>
        <description>Endpoint: Stroke</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <description>Endpoint: Stroke</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stroke at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.492</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.148</ci_lower_limit>
            <ci_upper_limit>1.637</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiovascular Related Hospitalizations</title>
        <description>Endpoint: Number of Cardiovascular hospitalizations per subject</description>
        <time_frame>Implant to 4 years post-implant</time_frame>
        <population>All participants were followed for 4 years. Those not hospitalized were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiovascular Related Hospitalizations</title>
          <description>Endpoint: Number of Cardiovascular hospitalizations per subject</description>
          <population>All participants were followed for 4 years. Those not hospitalized were excluded from the analysis.</population>
          <units>Number of CV Hospitalizations</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical test for Number of subjects with CV hospitalization</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Cardiovascular Related Hospitalizations</title>
        <description>Endpoint: Duration of Cardiovascular Hospitalizations per subject</description>
        <time_frame>Implant to 4 years post-implant</time_frame>
        <population>All participants were followed for 4 years. Those not hospitalized were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on
Managed Ventricular Pacing programmed ON/OFF: Device programming</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing
Managed Ventricular Pacing programmed ON/OFF: Device programming</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Cardiovascular Related Hospitalizations</title>
          <description>Endpoint: Duration of Cardiovascular Hospitalizations per subject</description>
          <population>All participants were followed for 4 years. Those not hospitalized were excluded from the analysis.</population>
          <units>Days of CV hospitalizations</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O2" value="7.5" lower_limit="3" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Class I Pacemaker (Implantable Pulse Generator = IPG) Indication in Implantable Cardioverter Defibrillator (ICD) Patients</title>
        <description>Endpoint: Patient implanted with a replacement ICD developing a class 1 pacemaker indication</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Class I Pacemaker (Implantable Pulse Generator = IPG) Indication in Implantable Cardioverter Defibrillator (ICD) Patients</title>
          <description>Endpoint: Patient implanted with a replacement ICD developing a class 1 pacemaker indication</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PR Interval, Change in QRS Duration and Change in P-wave Duration</title>
        <description>Endpoint: Change in PR interval, Change in QRS duration and Change in P-wave duration evaluated at enrollment and 24 Month FU</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PR Interval, Change in QRS Duration and Change in P-wave Duration</title>
          <description>Endpoint: Change in PR interval, Change in QRS duration and Change in P-wave duration evaluated at enrollment and 24 Month FU</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval (ms) difference 24 month-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="60.9"/>
                    <measurement group_id="O2" value="10.8" spread="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration (ms) difference: 24 month-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="32.4"/>
                    <measurement group_id="O2" value="10.8" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P-wave duration (ms) difference: 24 month-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="41.2"/>
                    <measurement group_id="O2" value="1.1" spread="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0:Change in P-R interval=Change in P-R interval Ha:Change in P-R interval≠Change in P-R interval</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0:Change in QRS duration=Change in QRS duration Ha:Change in QRS duration≠Change in QRS duration</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0:Change in P-wave duration=Change in P-wave duration Ha:Change in P-wave duration≠Change in P-wave duration</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Symptoms</title>
        <description>Endpoint: Symptoms evaluated at enrollment, 12 months and 24 months followup</description>
        <time_frame>Implant to 2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Symptoms</title>
          <description>Endpoint: Symptoms evaluated at enrollment, 12 months and 24 months followup</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No symptoms (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness/presyncope (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Symptoms (12 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain (12 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea (12 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness/presyncope (12 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Symptoms (24 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain (24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea (24 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness/presyncope (24 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No Symptoms (Baseline)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No Symptoms (12 months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.92</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No Symptoms (24 Months)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrial Pacing Percentage</title>
        <description>Endpoint: Cumulative percentage atrial pacing documented in the device memory</description>
        <time_frame>2 years post-implant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Pacing Percentage</title>
          <description>Endpoint: Cumulative percentage atrial pacing documented in the device memory</description>
          <units>percentage atrial pacing</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="36" upper_limit="94"/>
                    <measurement group_id="O2" value="78" lower_limit="47" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health State</title>
        <description>Endpoint: Health State evaluation with the EQ-5D questionnaire (range 0-100) . A measure of 100 is better and a measure of 0 is worse.</description>
        <time_frame>2 years post-implant</time_frame>
        <population>Patients with health evaluation completed at 24 months follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>MVP ON</title>
            <description>Managed Ventricular Pacing programmed on</description>
          </group>
          <group group_id="O2">
            <title>MVP OFF</title>
            <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
          </group>
        </group_list>
        <measure>
          <title>Health State</title>
          <description>Endpoint: Health State evaluation with the EQ-5D questionnaire (range 0-100) . A measure of 100 is better and a measure of 0 is worse.</description>
          <population>Patients with health evaluation completed at 24 months follow-up</population>
          <units>units on a Health State scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" spread="17.2"/>
                    <measurement group_id="O2" value="70.3" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline until study closure. The following abbreviations are used in the additional description: SAE: serious adverse event. (S)ADE: (serious) adverse device effect. PE: primary endpoint.</time_frame>
      <desc>The following adverse events had to be reported:
SAEs (for study purposes also included: 1) cardioversion and 2) emergency room / office visits resulting in acute treatment for worsened cardiac condition
Deaths
(S)ADE
The PE committee adjudicated all reported AEs per the primary objective. No further classification has been done.</desc>
      <group_list>
        <group group_id="E1">
          <title>MVP ON</title>
          <description>Managed Ventricular Pacing programmed on</description>
        </group>
        <group group_id="E2">
          <title>MVP OFF</title>
          <description>Managed Ventricular Pacing programmed off: conventional pacing</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>First cardiovascular hospitalization within 2 years after implant</sub_title>
                <description>Hospitalization (including emergency room) for cardiovascular causes: new or worsening heart failure, angina, myocardial infarction, any arrhythmia, stroke, transient ischemic attack, acute peripheral vascular emergencies, pulmonary embolism.</description>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="299"/>
                <counts group_id="E2" events="40" subjects_affected="40" subjects_at_risk="306"/>
              </event>
              <event>
                <sub_title>Cardioversion within 2 years after implant</sub_title>
                <description>Cardioversion medically or electrically</description>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="299"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death from any cause within 2 years after implant</sub_title>
                <description>All cause death</description>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="299"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke within 2 years after implant</sub_title>
                <description>Stroke</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="299"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="299"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non serious adverse events up to 2 years follow-up</sub_title>
                <description>All reported adverse events which were not serious</description>
                <counts group_id="E1" events="47" subjects_affected="32" subjects_at_risk="299"/>
                <counts group_id="E2" events="39" subjects_affected="31" subjects_at_risk="306"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Atrial pacing % was not collected at implant, device programming in the MVP off arm was more often non-compliant than in MVP on arm, and 25% of the case report forms were sent without device data, possibly influencing device data related objectives</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lidwien Vainer</name_or_title>
      <organization>Medtronic Bakken</organization>
      <phone>+31 433566752</phone>
      <email>lidwien.vainer@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

